Cliff Ledger Research & Insights Hub
Every empirical study below is generated deterministically from Cliff Ledger publication c7aa149ae887ad06ebb0, uniting 22,438 FDA Orange Book patent rows, Drugs@FDA regulatory histories, deduplicated CMS Part D plus Medicaid reimbursement ($399.94B), and California HCAI SB 17 Wholesale Acquisition Cost and specialty drug launch disclosures.
The 2026 to 2030 Pharmaceutical Patent Cliff: Reconciled FDA Orange Book LOE Windows and Medicare Part D plus Medicaid Exposure
Molecule-by-molecule audit of 91 blockbuster NDAs ($111.06B CMS spend) losing core FDA Orange Book patent protection between 2025 and 2030.
Reported Wholesale Price Changes Ahead of Patent Expiration: 89 Blockbuster Drugs With California HCAI SB 17 Filings and $51.58B CMS Spend
Empirical audit of 5,355 California HCAI SB 17 Wholesale Acquisition Cost filings identifying 89 near-LOE brand drugs ($51.58B CMS spend) above the 16% statutory threshold.
Specialty Drug Launch Pricing Above the Medicare Part D Threshold: California HCAI SB 17 New Drug Introduction Analysis
Analysis of 2,161 California HCAI SB 17 new drug market-introduction filings and 610 specialty therapies launching up to $285,000 introductory WAC.
Orphan and Biologic Exclusivity Stacking: Why High-Spend Drugs Delay Generic and Biosimilar Entry Past Primary Patent Expiration
Empirical study of 367 BLA biologics ($70.88B CMS spend), serial 7-year Orphan Drug Exclusivities, and 14 off-patent single-source brand NDAs.